Manus Bio

What Manus Bio does

Manus Bio Inc. is a Waltham, Massachusetts-based industrial biotechnology company that operates a precision fermentation platform for producing bioalternatives — chemically identical replacements for complex molecules traditionally sourced from plants, animals, or fossil fuels. The company's core technology is its proprietary BioOptimization Cycle, which integrates metabolic engineering, AI-augmented enzyme engineering, and systems biology, supported by a Universal Chassis Collection of engineered microorganisms and an Integrated Multivariate Omics Analysis platform. This stack is protected by more than 200 patents and is built on more than two decades of digital biological data.

Manus commercializes a portfolio of bio-manufactured ingredients including Monk Fruit Sweetener (the first U.S.-made monk fruit sweetener at commercial scale), Yume M Stevia Reb M (in partnership with Tate & Lyle through The Natural Sweetener Alliance), and citrus BioIngredients such as BioNootkatone, Valencene 80, and Nootkatone 70 (developed and scaled for Givaudan). The company also runs two service programs — the BioAccelerator Program for end-to-end bioalternative development and the BioManufacturing Program for scale-up capacity — and licenses the MAD7 CRISPR nuclease acquired via the 2025 Inscripta merger. Manufacturing is anchored by the Augusta, Georgia BioFacility, which houses 40K L and 600K L fermentors with peak capacity of 6,000 metric tons annually, plus a raw materials facility in Paita, Peru and a new application hub in Singapore for the Asia-Pacific region.

Manus earns revenue primarily through direct B2B sales of manufactured ingredients to food and beverage, flavor and fragrance customers, supplemented by distribution partnerships with Tate & Lyle and Givaudan, government contracts with HHS ASPR for essential medicines, service fees from BioAccelerator and BioManufacturing engagements, and royalties from MAD7 CRISPR licensing. The company is privately held, has 101-250 employees, and has been funded primarily through non-dilutive sources including a $47.4M HHS ASPR award, a $2M Gates Foundation grant, multiple NSF awards, and a $75M round in 2020.

Name

Manus Bio

Legal name

Manus Bio Inc.

Website

https://manusbio.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Manus Bio is an industrial biotechnology company that uses engineered cell factories and precision fermentation to produce bioalternative sweeteners, flavors, and pharmaceutical ingredients for food and beverage, flavor and fragrance, and U.S. government customers, with commercial-scale manufacturing in Augusta, Georgia.

Ownership category

akta.pro rank

Product category

Industrial Biotechnology Ingredients (Bioalternatives)

NAICS

Food Manufacturing (311), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Food And Kindred Products (2000), Medicinal Chemicals & Botanical Products (2833), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Bio-based Food & Flavor Ingredients (Non-fuel Co-products: sweeteners, organic acids, flavors) (EUAAAIAJ)

akta.pro secondary industries

Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM), Bio-based Platform & Commodity Chemicals (e.g., bio-ethylene, bio-propylene, bio-BTX, bio-methanol) (EUAAAIAA)

Keywords

• Precision fermentation ingredients
• Bioengineered cell factories
• Natural sweetener manufacturing
• Biomanufacturing scale-up services
• Industrial biotechnology platform

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Bioalternative Product Sales: Manus manufactures and sells bioalternative ingredients (sweeteners, flavors, fragrances) directly to food and beverage companies. Revenue is generated from the sale of these manufactured ingredients, including Monk Fruit Sweetener, Yume M Stevia, BioNootkatone, Valencene 80, and Nootkatone 70.
2. BioAccelerator Program: End-to-end development service for companies needing complete solutions - from cell factory engineering to biomanufacturing at scale. Provides protein engineering, strain development, bioprocess development, pilot scale, and research services to help partners bring bioalternative products to market.
3. BioManufacturing Program: Scale-up and biomanufacturing services using Manus' state-of-the-art BioFacilities for companies looking to expand production capacity. Includes pilot scale services and research services for techno-economic data collection.
4. Licensing: Manus licenses its CRISPR tools (MAD7) to broaden access to genome-editing technology, generating licensing revenue from biotech and research institutions.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Manus Bio operates a bioalternatives scale-up platform that uses engineered microbial cell factories and precision fermentation to manufacture sustainable, chemically identical versions of complex molecules traditionally sourced from plants, animals, or fossil fuels. The company sells bioalternative ingredients (Monk Fruit Sweetener, Yume M Stevia, BioNootkatone, Valencene 80, Nootkatone 70) directly to enterprise food, beverage, flavor, fragrance, and pharmaceutical customers, and also provides development and biomanufacturing service programs plus licensing of MAD7 CRISPR tools.

Product overview

Manus Bio operates as a bioalternatives scale-up platform offering a portfolio of bio-manufactured ingredients and supporting technology programs. The core products include Monk Fruit Sweetener (the first US-made monk fruit sweetener at commercial scale), Yume™ M Stevia Sweetener (bioconverted Reb M under The Sweetener Alliance with Tate & Lyle), BioNootkatone (citrus bioalternative developed with Givaudan), and Valencene 80/Nootkatone 70 (citrus BioIngredients). These are complemented by the proprietary BioOptimization Cycle® technology platform and two service programs: the BioAccelerator Program (end-to-end development) and BioManufacturing Program (scale-up and production capacity). The company also licenses MAD7™ CRISPR tools. The platform leverages engineered cell factories and precision fermentation to produce complex molecules sustainably.

Differentiator

Problem solved

Functional benefit

Brands

• Yume™ M Stevia Sweetener: Premium stevia-derived sweetener (Reb M) produced at Manus' BioFacility in Augusta, Georgia, through partnership with Tate & Lyle under The Sweetener Alliance. First large-scale commercialization of an all-Americas-sourced, manufactured, and bioconverted stevia Reb M ingredient.
• Monk Fruit Sweetener
• BioNootkatone
• Nootkatone 70
• Valencene 80
• MAD7™

Products and services

• Monk Fruit Sweetener Zero-calorie, non-glycemic monk fruit sweetener approximately 350 times sweeter than sugar, produced via precision fermentation at the Augusta BioFacility. The first monk fruit sweetener manufactured at commercial scale in the United States, offering clean rounded sweetness for dairy, nutritional products, and beverage applications.
• Yume M Stevia Sweetener Premium stevia-derived sweetener (Reb M) produced through bioconversion at Manus' Augusta BioFacility. Marketed under The Sweetener Alliance partnership with Tate & Lyle for global distribution to food and beverage customers.
• BioNootkatone Bioalternative to nootkatone, a rare component found in citrus fruits. Developed and scaled in partnership with Givaudan for flavor and fragrance applications. Reduces the input required from approximately 400,000 kg of fruit to just a few kg of sugar per kilogram of nootkatone oil.
• Valencene 80 and Nootkatone 70 Citrus BioIngredients produced from lab to manufacturing through Manus' bioalternatives scale-up platform. Deliver taste and sensory performance while reducing dependency on volatile agricultural supplies. Produced for Givaudan.
• BioAccelerator Program End-to-end development service program bridging the Valley of Death for partner companies. Provides protein engineering, strain development, bioprocess development, and pilot scale services to optimize and accelerate each step of bioalternative product development.
• BioManufacturing Program Program enabling partner companies to expand scale-up and production capacity using Manus' state-of-the-art BioFacilities. Provides pilot scale and research services for pre-commercial testing, regulatory submissions, and full-scale engineering designs.
• MAD7 CRISPR Tools Licensing Licensing of MAD7, a best-in-class CRISPR genome-editing nuclease obtained through the Inscripta-Manus merger. Offered as a powerful, flexible, and cost-effective tool for genome editing across biotech and research institutions.

Quantifiable outcome

• Cell factories are more than 1,000 times more efficient than nature in producing bioalternative molecules
• +8 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Partnerships

Six partnerships are on record, tiered notable, strategic, regional, flagship and core.

• U.S. Congress / HHS LeadershipnotableOthers · 6 May 2026Groundbreaking ceremony for artemisinin biomanufacturing facility attended by HHS ASPR Principal Deputy Assistant Secretary John Knox, U.S. Rep. Rick Allen (R-Ga.), and U.S. Rep. Buddy Carter (R-Ga.). The event underscores Manus' role in advancing America's biomanufacturing leadership and national security capabilities.
• University of GeorgiastrategicStrategic or Co-development Partner · 30 April 2026Academic partnership for the BioMADE-supported apprenticeship program. UGA provides academic expertise to develop a transferable curriculum and implementation blueprint for training biomanufacturing operators. The blueprint can serve as a replicable mechanism for workforce development at scale across bioindustrial facilities.
• BioMADEstrategicStrategic or Co-development Partner · 30 April 2026National manufacturing innovation institute for industrial biotechnology selected Manus' apprenticeship program through a competitive project call. BioMADE advances its mission to strengthen domestic bioindustrial manufacturing and grow a skilled U.S. manufacturing workforce. Project supports BioMADE's goal of creating a replicable training blueprint for bioindustrial facilities across the U.S.
• Asia-Pacific Regional PartnersregionalChannel Partner/ Reseller/ Distributor · 5 February 2026Manus opened a purpose-built application hub in Singapore to serve customers and partners across the Asia-Pacific region. The hub provides hands-on product development, formulation optimization, and application support tailored to regional needs, establishing local presence to help companies integrate advanced biobased solutions.
• Tate & LyleflagshipStrategic or Co-development Partner · 29 October 2024Strategic partnership known as 'The Natural Sweetener Alliance' to expand access to natural sugar reduction solutions. First product is stevia Reb M (Yume M Stevia), marking the first large-scale commercialization of an all-Americas-sourced, manufactured, and bioconverted stevia Reb M ingredient. Tate & Lyle brings stevia R&D, sensory expertise, applications knowledge, nutrition expertise, regulatory expertise, and global presence. Manus provides bioconversion technology, manufacturing, and supply chain control from stevia leaf to final ingredient.
• GivaudancoreStrategic or Co-development Partner · 1 January 2022Development and scaling partnership through the BioAccelerator Program to develop BioNootkatone - a bioalternative to nootkatone, one of the rare components found in citrus fruits. Givaudan contributed analytical, flavor, and processing expertise. Portfolio also includes Valencene 80 and Nootkatone 70 produced for Givaudan. The partnership reduced inputs and resources required to produce 1 kg of nootkatone oil from approximately 400,000 kg of fruit to only a few kg of sugar.

Scale indicators12 records

Recent moves10 records

Expansion highlights7 records

Broad incumbents

• dsm-firmenich: dsm-firmenich is a global leader in nutrition, health, and flavors & fragrances, with active investments in fermentation-derived ingredients including alternative proteins and bioactives. Comparable to Manus Bio as a flavor customer/supplier partner and as a vertically integrated ingredient platform pursuing precision fermentation partnerships.
• Tate & Lyle: Tate & Lyle is a global food ingredient supplier and Manus Bio's primary sweetener distribution partner through The Natural Sweetener Alliance (Yume M Stevia). Comparable as both a partner and broader food ingredient incumbent with overlapping interests in stevia, monk fruit, and sugar reduction.
• Cargill: Cargill is a global agribusiness and food ingredient supplier with growing investments in fermentation and bio-based ingredients (e.g., EverSweet stevia via partnership). Comparable to Manus Bio as a major food ingredient incumbent with both partnership potential and competitive overlap in stevia and bio-sweeteners.
• Novonesis: Novonesis (formed from the Novozymes/Chr. Hansen merger) is the global leader in industrial enzymes, fermentation, and microbial solutions for food, agriculture, and health. Comparable to Manus Bio as a large-scale fermentation incumbent with overlapping applications in food ingredients, flavors, and bioactives, though much broader portfolio and global distribution.
• Givaudan: Givaudan is the world's largest flavor and fragrance house and is Manus Bio's flagship development partner for BioNootkatone, Valencene 80, and Nootkatone 70. Comparable as both customer and competitor in the bioalternative flavor space, with broad F&F portfolio and global reach.

Direct peers

• Amyris: Amyris pioneered precision fermentation for ingredients including sweeteners, flavors, and cosmetic actives. Despite its 2023 bankruptcy and asset restructuring, its successor entities continue operating in overlapping product categories with Manus Bio (squalane, Reb M, nootkatone), making it a structural reference point for both opportunity and execution risk in the space.
• Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology platform that programs cells for customers across food, agriculture, and industrial biotech. Comparable to Manus Bio's BioAccelerator/BioManufacturing service model and chassis engineering capability, though Ginkgo is more platform/codebase-oriented while Manus is vertically integrated through commercial manufacturing.
• Conagen: Conagen is a precision fermentation company developing bio-based ingredients across food, flavor, fragrance, and pharmaceutical end-markets using engineered microbes. Directly comparable to Manus Bio in technology approach (cell factory engineering) and product categories (sweeteners, flavors, vitamins, APIs), making it the closest head-to-head competitor.

Emerging players

• Codexis: Codexis engineers enzymes and proteins for pharmaceutical and sustainable chemistry applications. Comparable to Manus Bio's AI-augmented enzyme engineering capability and computational protein design platform, with overlap in pharma ingredient manufacturing though smaller scale and different commercial focus.

Others

• BioMADE: BioMADE is a U.S. Department of Defense-sponsored national manufacturing innovation institute for industrial biotechnology. Comparable to Manus Bio as a strategic ecosystem partner (Manus participates in BioMADE-supported apprenticeship program) rather than a direct competitor — relevant for understanding the U.S. biomanufacturing policy landscape Manus operates within.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/manusbio
• LinkedInlinkedin.com/company/manus-biosynthesis

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds14 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Manus Bio